SCHEMBL17204101

SCHEMBL17204101

Clc1cc(N2CCOCC2)nc(N2CCOCC2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.61
▸ CYP1A2 P05177 3/20 0.61
▸ CYP2D6 P10635 1/20 0.61
▸ KMT2A Q03164 4/20 0.56
▸ RAB9A P51151 2/20 0.54
▸ MEN1 O00255 2/20 0.54
▸ NPC1 O15118 1/20 0.54
▸ HTT P42858 1/20 0.51
▸ CRHBP P24387 1/20 0.51
▸ CRHR2 Q13324 1/20 0.51
▸ CNR2 P34972 3/20 0.49
▸ PIK3CB P42338 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ POLB P06746 1/20 0.49
▸ TSHR P16473 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ CYP3A4 P08684 2/20 0.47
▸ CYP2C9 P11712 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29434159 0.90 MAPT (0.65) MAPTCYP1A2CYP2D6KMT2ARAB9A
SCHEMBL971891 0.90 MAPT (0.65) MAPTCYP1A2CYP2D6KMT2ARAB9A
SCHEMBL29434160 0.90 MAPT (0.65) MAPTCYP1A2CYP2D6KMT2ARAB9A
SCHEMBL29762483 0.87 MAPT (0.61) MAPTCYP1A2CYP2D6KMT2ARAB9A
SCHEMBL245771 0.87 MAPT (0.61) MAPTCYP1A2CYP2D6KMT2ARAB9A
SCHEMBL23299977 0.87 MAPT (0.53) MAPTCYP1A2CYP2D6KMT2ARAB9A
SCHEMBL913213 0.87 KMT2A (0.63) MAPTCYP1A2CYP2D6KMT2ARAB9A
SCHEMBL29434148 0.84 CYP1A2 (0.50) MAPTCYP1A2CYP2D6KMT2ARAB9A
SCHEMBL24766463 0.84 CYP1A2 (0.50) MAPTCYP1A2CYP2D6KMT2ARAB9A
SCHEMBL856718 0.83 MAPT (0.61) MAPTCYP1A2CYP2D6KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10766874-B2 Manufacturing process for triazine, pyrimidine and pyridine derivatives UNIVERSITAET BASEL (CH) 2020-09-08 — — US disclosed
US-10766874-B2 Manufacturing process for triazine, pyrimidine and pyridine derivatives UNIVERSITAET BASEL (CH) 2020-09-08 — — US disclosed
US-20190016698-A1 NOVEL MANUFACTURING PROCESS FOR TRIAZINE, PYRIMIDINE AND PYRIDINE DERIVATIVES TORQUR AG (CH) 2019-01-17 — — US disclosed
US-20190016698-A1 NOVEL MANUFACTURING PROCESS FOR TRIAZINE, PYRIMIDINE AND PYRIDINE DERIVATIVES TORQUR AG (CH) 2019-01-17 — — US disclosed
EP-3134388-B1 NOVEL MANUFACTURING PROCESS FOR TRIAZINE, PYRIMIDINE AND PYRIDINE DERIVATIVES UNIV BASEL (CH) 2019-01-09 — — EP disclosed
EP-3134388-B1 NOVEL MANUFACTURING PROCESS FOR TRIAZINE, PYRIMIDINE AND PYRIDINE DERIVATIVES UNIV BASEL (CH) 2019-01-09 — — EP disclosed
US-10100031-B2 Manufacturing process for triazine, pyrimidine and pyridine derivatives UNIVERSITAET BASEL (CH) 2018-10-16 — — US disclosed
EP-3134388-A1 NOVEL MANUFACTURING PROCESS FOR TRIAZINE, PYRIMIDINE AND PYRIDINE DERIVATIVES Universität Basel (CH) 2017-03-01 — — EP disclosed
US-20170037027-A1 NOVEL MANUFACTURING PROCESS FOR TRIAZINE, PYRIMIDINE AND PYRIDINE DERIVATIVES TORQUR AG (CH) 2017-02-09 — — US disclosed
US-20170037027-A1 NOVEL MANUFACTURING PROCESS FOR TRIAZINE, PYRIMIDINE AND PYRIDINE DERIVATIVES TORQUR AG (CH) 2017-02-09 — — US disclosed
US-20170037027-A1 NOVEL MANUFACTURING PROCESS FOR TRIAZINE, PYRIMIDINE AND PYRIDINE DERIVATIVES TORQUR AG (CH) 2017-02-09 — — US disclosed
WO-2015162187-A1 DEWATERING OF SLUDGE SOLENIS TECHNOLOGIES CAYMAN LP (CH) 2015-10-29 — — WO disclosed
WO-2015162084-A1 NOVEL MANUFACTURING PROCESS FOR TRIAZINE, PYRIMIDINE AND PYRIDINE DERIVATIVES UNIVERSITAET BASEL (CH) 2015-10-29 — — WO disclosed
WO-2015162084-A1 NOVEL MANUFACTURING PROCESS FOR TRIAZINE, PYRIMIDINE AND PYRIDINE DERIVATIVES UNIVERSITAET BASEL (CH) 2015-10-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190016698-A1 NOVEL MANUFACTURING PROCESS FOR TRIAZINE, PYRIMIDINE AND PYRIDINE DERIVATIVES IL5, WIZ, TPMT MAPT 2285/4885CYP1A2 368/4885CYP2D6 208/4885
US-10100031-B2 Manufacturing process for triazine, pyrimidine and pyridine derivatives IL5, WIZ, TPMT MAPT 2255/4885CYP1A2 382/4885CYP2D6 222/4885
US-20170037027-A1 NOVEL MANUFACTURING PROCESS FOR TRIAZINE, PYRIMIDINE AND PYRIDINE DERIVATIVES IL5, WIZ, TPMT MAPT 2649/4885CYP1A2 318/4885CYP2D6 200/4885
US-10766874-B2 Manufacturing process for triazine, pyrimidine and pyridine derivatives IL5, WIZ, TPMT MAPT 2518/4885CYP1A2 468/4885CYP2D6 299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback